Skip to main content
. 2016 Aug 29;7(40):65284–65294. doi: 10.18632/oncotarget.11673

Table 2. Expression of T-bet and GATA3 in 109 PTCL tumor samples by immunohistochemistry.

T-bet GATA-3
No. + ++ No. + ++
PTCL-NOS 60 34 (56.7) 21 (35.0) 5 (8.3) 60 35 (58.3) 21 (35.0) 4 (6.7)
NKT 18 10 (55.6) 4 (22.2) 4 (22.2) 18 8 (44.4) 9 (50.0) 1 (5.6)
AITL 11 8 (72.7) 3 (27.3) 0 (0.0) 11 3 (27.3) 6 (54.5) 2 (18.2)
ALK+ ALCL 4 2 (50.0) 2 (50.0) 0 (0.0) 4 0 (0.0) 2 (50.0) 2 (50.0)
ALK- ALCL 4 2 (50.0) 1 (25.0) 1 (25.0) 4 3 (75.0) 1 (25.0) 0 (0.0)
Others 12 7 (58.3) 4 (33.3) 1 (8.3) 12 10 (83.3) 1 (8.3) 1 (8.3)
Total 109 63 (57.8) 35 (32.1) 11 (10.1) 109 59 (54.1) 40 (36.7) 10 (9.2)